^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1293P - KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations
Published date:
09/13/2021
Excerpt:
ORR (confirmed PR) was 50% (6/12; 95% CI: 21.1‒78.9). Disease control rate (DCR) was 91.7% (11/12; 95% CI: 61.5–99.8). 5 pts had best response of SD and 1 patient had PD. Median PFS was 8.7 months (95% CI: 4.1, NE). Median overall survival (OS) was not reached, and OS rate was 100% at 6 months....KN046 combined with platinum-based chemotherapy is well tolerated and has demonstrated promising, albeit preliminary anti-tumor activity as 1L treatment for stage IV NSCLC pts with resistant oncogenic driver alterations (including EGFR and HER2 exon 20 insertion mutation, EGFR amplification, RET fusion).
Secondary therapy:
Chemotherapy
Trial ID:
